Regarding pancreatic cancer, Olaparib is the only PARP inhibitor that has been FDA-approved for usage in patients with pancreatic cancers with BRCA1 or BRCA2 mutations. The gene discussed is BRCA2; the disease is familial pancreatic carcinoma.